Abstract: Low levels of serum vitamin D are common in patients with mood disorders and stroke. It has been shown that low levels of serum vitamin D indicate a risk of depression in post-stroke subjects. Our aim was to determine the relationship between vitamin D and post-stroke anxiety (PSA).
INTRODUCTION
M ental disorders such as anxiety and depression are a particularly frequent and important complication of stroke. Compared with post-stroke depression, anxiety after stroke has been relatively neglected. Previous studies have found that approximately a quarter of stroke patients experience post-stroke anxiety (PSA). 1, 2 Several studies have also noted that 21% of patients suffered from moderate or severe anxiety 3 months after a stroke, 3 whereas the frequency of PSA was 18% at 2 years. 4 Many factors have been demonstrated to be correlated with the development of PSA, including gender, 4, 5 age, 4 lesion location, 6 ,7 severity of cognitive impairment, 3, 8 and activities of daily living. 4 Previous studies have strongly suggested that symptoms of anxiety negatively influence rehabilitation and long-term outcomes. 9, 10 Therefore, early recognition and treatment of PSA is of great importance to reduce stroke complications and mortality as well as to improve functional outcomes. However, the underlying pathophysiological mechanisms of the development of PSA remain unclear.
Vitamin D has been proposed to be a neurosteroid hormone in the central nervous system and plays an important role in the development of the brain. Vitamin D receptor (VDR) and tryptophan hydroxylase, which are required for the synthesis of the active metabolite, are widely present in the brain. 11, 12 Vitamin D plays diverse biological roles in certain mental processes, such as enabling neuroprotection, 12 regulating neurotrophic signaling, 13 and influencing inflammation. 14, 15 Previous studies have suggested that a deficiency in Vitamin D is linked with a wide range of nervous system diseases, including Alzheimer disease, 16 Parkinson disease, 16 and multiple sclerosis. 17 Multiple lines of evidence have indicated that low serum levels of vitamin D are prevalent in the majority of acute stroke patients 18, 19 and can be regarded as a potential risk factor for stroke. 19, 20 Furthermore, it has been reported that low serum concentrations of vitamin D in stroke patients might contribute to a higher morbidity and mortality. 21 Additionally, vitamin D supplementation has been found to decrease the incidence of stroke and improve the outcome of patients. 19, 21 There is a growing body of evidence suggesting a strong relationship between vitamin D deficiency and emotional disorders including depression and anxiety. 22, 23 A large crosssectional study revealed that higher vitamin D levels could significantly reduce the risk of depression in healthy populations. 24 A relationship between lower levels of vitamin D and depression have been documented in depressed patients. 25 Given the similar neural pathways to depression, low levels of vitamin D have also been found in patients with anxiety disorder. 26 Moreover, animal experiments have demonstrated that mice with a vitamin D deficiency showed an increase in anxiety-like behaviors.
Vitamin D deficiency is very common in stroke patients and has been related to the development of post-stroke depression. 27, 28 Nevertheless, the effects of vitamin D on the incidence of PSA remain unclear. Therefore, we conducted this study to explore the potential association between serum levels of vitamin D and the development of PSA.
METHODS

Subjects
This research was conducted in the First Affiliated Hospital of Wenzhou Medical University. Patients within 7 days of stroke onset who were between the ages of 18 and 80 years old were recruited from October 2013 to September 2014. The diagnosis of acute ischemic stroke was supported by computed tomography scanning and/or magnetic resonance imaging. The exclusion criteria included patients with the following characteristics: (1) a decreased level of consciousness or severe cognitive dysfunction, aphasia, or dysarthria; (2) a history of anxiety disorder or other psychiatric disorder; (3) a history of stroke or any central nervous system disease such as Parkinson disease, dementia, or a tumor; and (4) the presence of severe physical diseases that resulted in an inability to follow up. Every patient signed an informed consent form. A total of 100 healthy subjects with a similar age and gender were recruited as controls. This study followed ethical guidelines and obtained the approval of the Institutional Review Board of the First Affiliated Hospital of Wenzhou Medical University.
Clinical Characteristics
All demographics characteristics including age, gender, marital status, educational status, and economic status were collected at baseline. Stroke severity was assessed by the National Institutes of Health Stroke Scale (NIHSS) at admission and 1 month. Stroke outcomes were measured by the modified Rankin scale (mRS) and the Barthel index (BI), and cognition function was assessed by the mini-mental state examination (MMSE) at 1 month.
All of the patients were screened for anxiety symptoms using the Hamilton anxiety scale (HAMA) at 1 month. Subjects with a HAMA anxiety score >7 were considered to have existing symptoms of anxiety.
Measurement of Vitamin D
Blood samples were collected using tubes with ethylene diamine tetra-acetic acid anticoagulant and were centrifuged to collect patient serum within 24 hours of admission. Because of its widespread clinical application and standardized ranges, we chose serum 25- 
Statistical Analysis
The Mann-Whitney U test, Student t test, or x 2 test were appropriately used to determine the differences between groups. Nonlinear variables were performed with logit-transformation for linear distributions. Logistic regression was employed to analyze independent risk factors of PSA. All statistical analyses were performed using SPSS for Windows (Release 19.0; SPSS, Chicago, IL). A P-value <0.05 was considered statistically significant.
RESULTS
In this study, a total of 552 first acute ischemic stroke patients were screened, with 226 finally enrolled. The mean age was 63.13 years, and 37.16% were women. Sixty cases showed anxiety, and the incidence of PSA was 26.55% at 1 month after stroke. The background characteristics of the participants are shown in Table 1 . We did not find significant differences between PSA and non-PSA patients in age (P ¼ 0.81), sex (M/F) (P ¼ 0.25), body mass index (BMI) (P ¼ 0.38), or education (P ¼ 0.26). Compared with the non-PSA group, the PSA group had more severe stroke (NIHSS score 2(0-12) vs 3(0-14), P ¼ 0.02), poorer cognitive function (MMSE score 26(11-30) vs 24(10-30), P ¼ 0.04), worse functional outcome (mRS score 1(0-4) vs 3(0-4), P <0.001), and poorer activities of daily living (BI score 100(30-100) vs 95(30-100), P <0.001) ( Table 1) .
The mean level of serum vitamin D in stroke patients was 52.63 AE 19.14, which was much lower than that of normal subjects (66.54 AE 17.57, P <0.001). Serum vitamin D was found to be significantly lower in the PSA group than in the non-PSA group (47.48 AE 18.10 vs 54.49 AE 19.22, respectively, P ¼ 0.02). Moreover, the serum vitamin D of both these two groups was lower than that of controls. Next, we divided patients into four groups according to quartiles of serum vitamin D levels, and we found significant differences in patients in the lowest quartile (P ¼ 0.01) ( Table 2) .
With the last three quartiles of vitamin D levels used as the reference and the occurrence of PSA considered the dependent variable in the logistic analysis, serum concentration of vitamin D ( 38.48 nmol/L) were independently associated with an increased risk of PSA (odds ratios (OR) 2.49, 95% confidence interval (CI): 1.21-5.13, P ¼ 0.01) after adjusting for possible confounders. In addition, the MMSE scores at 1 month were significantly associated with the occurrence of PSA in first acute ischemic stroke patients (OR 0.92, 95% CI: 0.86-0.99, P ¼ 0.02) ( Table 3) .
DISCUSSION
To the best of our knowledge, this is the first study to explore the relationship between serum vitamin D levels and the occurrence of PSA. Our results revealed an inverse association between serum vitamin D levels and anxiety 1 month after stroke.
Previous studies have demonstrated that $11% to 54% of stroke patients experience anxiety symptoms, 3, 8, [29] [30] [31] [32] which was similar to our results. A meta-analysis of 41 studies reported a pooled PSA prevalence of 18% in the acute period, without finding a significant increase over time.
1 A 10-year follow-up study indicated that PSA was a common problem in a long-term observation, with a prevalence over 30% and an annual incidence of $20%.
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As a common and long-lasting complication, early recognition and treatment are particularly important, but the underlying mechanism of PSA has remained unclear. In our study, the serum concentration of vitamin D was found to be significantly lower in acute stroke patients than in healthy controls, which was consistent with previous studies. 18, 19 Moreover, a significant association between low serum levels of vitamin D and PSA was also found. This suggests that serum levels of vitamin D might be used as a biological marker of PSA.
Over the past decades, there have been a growing number of studies exploring the relationship between vitamin D and anxiety. 22, 23 Vitamin D could modulate anxiety symptoms through its effect on inflammation, as mediated by cytokines. 14 An increased level of C-reaction protein has been found in men with present anxiety disorder, 34 whereas the serum levels of vitamin D have been negatively correlated with various cytokines such as TNF-a and C-reaction protein. 15 Additionally, cytokines could lead to anxiety by altering the metabolism of neurotransmitters such as dopamine 35 and serotonin. 36 Interferon-alpha was found to downregulate glucocorticoid receptor and serotonin receptor 1A levels in cell lines, 36 which was believed to be closely connected with anxiety. Moreover, interferon-gamma knockout mice exhibited anxiogenic behavior. 37 The function of the hypothalamic-pituitary-adrenal (HPA) axis, which has been confirmed to be another plausible mechanism involved in the process of anxiety, is also influenced by cytokines. 38 A previous study demonstrated that interferon and tumor necrosis factor alpha (TNF-a) may contribute to altered diurnal HPA axis activity. 39 Multiple lines of evidence have suggested that vitamin D deficiency is prevalent in post-stroke patients because of decreased vitamin D intake and sunlight caused by limited mobility. 18, 19 The incidence of vitamin D deficiency in poststroke patients was found to be greater than that in other inpatients with general medical disease. 40 As a potent antiinflammatory agent, vitamin D might be involved in the development of PSA through its influence on the expression of cytokines and its mediation of inflammation. 24 A variety of cells in the brain including neurons, astrocytes, and microglia release bioactive cytokines. 25 Acute ischemic stroke can modulate the expression of cytokines in these cells. 41 Specific cytokines including interleukin-1 and TNF-a have been heavily implicated in acute stroke patients, 27, 42 and similar results have also been observed in ischemic brains of aged mice. 28 Vitamin D could reduce brain inflammation after brain injury. 43 In addition to the inflammation mentioned previously, vitamin D might also lead to PSA through its effect on the synthesis of neurotrophins. Vitamin D has been shown to regulate neurotrophic signaling. 44 The expression of several neurotrophic factors such as nerve growth factor, neurotrophin-3, and neurotrophin-4 has been found to be influenced by calcitriol (the primary active form of vitamin D), enhancing transmission of synaptic or regulatory calcium signaling. [45] [46] [47] Studies in animals have identified that serum levels of nerve growth factor are related to inducing anxiolytic-like behaviors in mice. 48 Furthermore, vitamin D mediates its function via binding to VRD and the enzyme 1a-hydroxylase, which are widely located in neuronal and glial cells of the human brain. 49 Previous studies have found that VDR knock-out mice showed increased anxiety symptoms. 50 Therefore, it was speculated that defects in the vitamin D-VDR system may directly result in anxiety. Hence, we can propose that low serum levels of vitamin D might play a critical role in the development of PSA.
Our results suggested that cognitive function decline after stroke was a risk factor for the development of PSA, which is broadly consistent with the findings of previous studies. 8 Meanwhile, no relationship was found between the development of PSA and other variables, including severity of stroke, 51 being female, 4, 5 and lesion location. 6, 7 There were several limitations to the present study. First, the serum level of vitamin D was tested only at admission, and thus further studies are required to explore how serum levels of vitamin D change dynamically after a stroke. Second, patients with severe cognitive dysfunction and aphasia were excluded, which may have introduced bias into our study. Third, the duration of follow-up might not have been long enough for us to distinguish ''true'' anxiety from ''reactive'' anxiety. Finally, the role of vitamin D-binding protein in anxiety was not studied. Studies with large samples and a long-term follow-up are needed to explore the relationship between vitamin D and PSA.
CONCLUSION
In summary, our study demonstrates that serum levels of vitamin D at admission were associated with the development of PSA. Moreover, vitamin D deficiency was considered an independent risk factor for PSA at 1 month. Further prospective studies are necessary to confirm this association and may contribute to the prevention and treatment of PSA. 
